Your session is about to expire
← Back to Search
Opioid
Methadone-Based Analgesia for Scoliosis Surgery
Phase 2
Waitlist Available
Led By Senthilkumar Sadhasivam, MD
Research Sponsored by Senthil Sadhasivam
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Children aged 10-<18 for PSF trial
Undergoing PSF for idiopathic scoliosis
Must not have
Neurological disease
Pregnant patients <18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1-week post-operative, week 1 post-discharge, month 1, and month 3
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to compare the use of a methadone-based recovery protocol to the current standard of care in children undergoing spinal surgery. Participants will be randomly assigned to one of the two groups, similar
Who is the study for?
This trial is for children undergoing elective spine fusion surgery to correct scoliosis, including idiopathic scoliosis. Specific eligibility criteria are not provided, but typically include a certain age range and health status.
What is being tested?
The study compares two post-surgery recovery protocols: one using methadone (a strong painkiller) and another with standard care that doesn't use methadone. Children will be randomly placed in either group by chance.
What are the potential side effects?
While specific side effects aren't listed, methadone can generally cause drowsiness, nausea, constipation, breathing problems, and potential dependency issues.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 10 and 17 years old.
Select...
I am having surgery for scoliosis not caused by other conditions.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a neurological condition.
Select...
I am pregnant and under 18.
Select...
I have been diagnosed with severe sleep apnea.
Select...
I have a serious health condition that limits my activity but is not incapacitating.
Select...
I have been using opioids before surgery.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1-week post-operative, week 1 post-discharge, month 1, and month 3
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1-week post-operative, week 1 post-discharge, month 1, and month 3
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Average postoperative pain scores
Total postoperative opioid use
Secondary study objectives
Generalized Anxiety Disorder-2 (GAD-2)
Length of Stay (LOS)
Opioid Dependence
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Methadone-Based ERAS GroupExperimental Treatment1 Intervention
Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
Group II: SOC Non-Methadone-Based GroupActive Control1 Intervention
Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
Find a Location
Who is running the clinical trial?
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,054 Previous Clinical Trials
2,731,134 Total Patients Enrolled
Senthil SadhasivamLead Sponsor
6 Previous Clinical Trials
3,700 Total Patients Enrolled
Senthilkumar Sadhasivam, MDPrincipal InvestigatorUniversity of Pittsburgh
2 Previous Clinical Trials
1,259 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger